HER2-Expressing Gastric Cancer Cells Respond to Treatment With Trastuzumab Deruxtecan
April 10th 2021For the treatment of patients with HER2-amplified gastric cancers in addition to those with HER2 moderate-, low-, and non-expressing disease, trastuzumab deruxtecan has shown to be an effective therapeutic option.
Read More
Zenocutuzumab Effectively Blocks Growth of NRG1 Fusion-Driven Tumors
April 10th 2021In NRG1 fusion–positive cell lines, zenocutuzumab demonstrated blockage of growth and cell death, as well as tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.
Read More
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
April 10th 2021In patient with metastatic uveal melanoma, frontline treatment with tebentafusp achieved significant and clinically meaningful improvement in overall survival, according to data from the phase 3 IMCgp100-202 trial.
Read More
Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHL
April 10th 2021Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.
Read More
Men With High Genetic Risk of Lethal Prostate Cancer May Lower Their Risk With a Healthier Lifestyle
April 10th 2021According to new research presented during the virtual AACR Annual Meeting 2021, the likelihood of developing metastatic disease or dying of prostate cancer among men with high genetic risk was lowered in men who maintained a healthy lifestyle.
Read More
Nivolumab/Chemotherapy Improves PCR as Neoadjuvant Treatment of Resectable NSCLC
April 10th 2021Neoadjuvant nivolumab added to chemotherapy lead to an improvement in pathological complete responses, compared with chemotherapy alone, as treatment of patients with resectable non-small cell lung cancer.
Read More
Apatinib/Doxorubicin Combination Improves PFS Over Single Agent in Ovarian Cancer
March 21st 2021The combination of apatinib and pegylated liposomal doxorubicin improved the progression-free survival for patients with platinum-resistant or refractory ovarian cancer in comparison to doxorubicin alone, according to data from the phase 2 APPROVE trial.
Read More
Niraparib Maintains PFS Improvement, But OS Data Are Limited in gBRCA+/- Ovarian Cancer
March 21st 2021Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.
Read More
CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.
Read More
Rucaparib Improves PFS in BRCA+ Relapsed Ovarian Cancer in Confirmatory ARIEL4 Trial
March 20th 2021Compared with standard-of-care chemotherapy, treatment with the PARP inhibitor rucaparib led to a significant prolongation of progression-free survival and improved duration of response in patients with BRCA-mutated advanced, relapsed ovarian cancer, according to primary results from the phase 3 ARIEL4 trial.
Read More
Niraparib Shows Efficacy in Hard-to-Treat Patients With Newly Diagnosed Ovarian Cancer
March 19th 2021Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.
Read More
Addition of Capivasertib to Chemotherapy May Not Be Beneficial in mCRPC
February 17th 2021Composite progression-free survival was not prolonged in patients with metastatic castration-resistant prostate cancer when the AKT kinase inhibitor capivasertib was added to chemotherapy. Despite this result, the combination demonstrated favorable overall survival.
Read More
Two Lenvatinib Combos Induce Survival Benefit Over Sunitinib in Advanced RCC
February 15th 2021Findings from the phase 3 CLEAR trial showed that the addition of lenvatinib to either pembrolizumab or everolimus led to an improvement in survival and response rates in comparison with sunitinib monotherapy in the first-line setting for patients with advanced renal cell carcinoma.
Read More
High Disease Control Rate Achieved With Belzutifan and Cabozantinib in ccRCC
February 15th 2021The addition of the oral hypoxia-inducible factor 2α inhibitor belzutifan to cabozantinib led to disease control in a majority of patients with previously treated advanced clear cell renal cell carcinoma, according to preliminary results from a phase 2 trial presented at the 2021 Genitourinary Cancers Symposium.
Read More
Cabozantinib Improves PFS Versus Sunitinib in Papillary RCC
February 14th 2021Cabozantinib reduced the risk of disease progression or death by 40% in comparison with sunitinib in patients with metastatic papillary renal cell carcinoma, according to findings from the randomized phase 2 SWOG 1500 study.
Read More
Fewer PSA Screenings May Be Associated With Metastatic Prostate Cancer Cases on the Rise
February 13th 2021An increase in metastatic prostate cancer cases were reported in the United States and investigators are suggesting that this may be due, in part, to reductions in prostate-specific antigen, according to epidemiologic data from a study presented during the 2021 Genitourinary Cancers Symposium.
Read More
Cabozantinib Induces Intracranial/Extracranial Responses in Metastatic RCC
February 13th 2021In patient with metastatic renal cell carcinoma who have brain metastases, treatment with cabozantinib displayed significant intracranial and extracranial, results from a retrospective analysis presented during the 2021 Genitourinary Cancers Symposium show.
Read More
Long-Term Responders of Apalutamide Identified With Molecular Signature in nmCRPC
February 13th 2021A molecular signature has been identified that can characterize long-term responders from treatment with apalutamide and androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, according to findings, presented at the 2021 Genitourinary Cancers Symposium.
Read More
High CR Achieved With Addition of N-803 to BCG in BCG-Unresponsive NMIBC CIS
February 13th 2021In patients with non-muscle invasive bladder cancer carcinoma in-situ who were unresponsive to Bacillus Calmette-Guerin, the addition of N-803 induced a high rate of complete responses, findings from a cohort of the phase 2/3 QUILT-3.032 study showed.
Read More
18F-DCFPyL, PSMA-Targeted PET Imaging Agent, Provokes High CLR and PPV
February 13th 2021Localized metastatic lesions were detected with a high correct localization rate (CLR) and positive predictive value (PPV) with the investigational prostate-specific membrane antigen (PSMA)–targeted PET imaging agent 18F-DCFPyL.
Read More